eligible ages (years): 18.0-65.0,  All  Arthritis Female Sexually active Heterosexual years undergoing THR (prospective) or having undergone THR surgery within the last year  Sexually inactive pre-operatively and wishing to remain sexually inactive post-operatively Unable to comprehend English and with capacity to consent and follow instruction Unable to sign and date the ethics committee approved consent documentation


A 47 year old male who fell on his outstretched left arm presents with pain and bruising on the inside and outside of the elbow, swelling, and inability to bend the arm. On the x-ray, the ulna has dislocated posteriorly from the trochlea of the humerus. The radius has dislocated from the capitulum of the humerus.

eligible ages (years): 18.0-65.0,  All  Spinal Cord Injuries Shoulder Impingement Syndrome Above 18 years old Have paraplegia as a result of a spinal cord injury morn than one year Able to perform push-ups independently and raise the arm above the head Self-propel a manual wheelchair as the primary means of mobility  Have history of fractures or dislocations in the shoulder, elbow, or wrist from which you have not fully recovered Have upper limb pain as a result of a complex regional pain syndrome Have a implant or pacemaker within the torso or upper arm Pregnant female


eligible ages (years): 18.0-70.0,  All  Basilar Invagination Associated With Atlantoaxial Dislocation Age between 18-70 Patients with cervical CT display that atlanto occipital fusion or partial fusion, Atlantoodontoid interval(ADI)>>3mm, odontoid tip over Qian line(CL)>>3mm Agreed to the surgical operation treatment The patient can carry out clinical follow-up and agree to long-term clinical follow-up Signed informed consent  Patients with traumatic atlanto-axial dislocation Patients with rheumatoid atlantoaxial dislocation Patients with a history of occipital cervical junction operation Patients with severe cerebellar tonsillar hernia (reach the C2 margin), needed to remove tonsil of cerebellum Patients during pregnancy and the postpartum period within 3 months The life expectancy of < 1 years Severe dementia(MMSE<18) Severe renal failure (CR > 2.5mg/dl) Serious cardiovascular disease (such as unstable angina, heart failure) Atrial fibrillation and other severe arrhythmia


eligible ages (years): 13.0-18.0,  All  Contraception Ages 13 to 18 years old Speaks English or Spanish Has menstrual periods Has Medicaid insurance  Seeking contraception as their primary complaint Currently pregnant based on urine or serum pregnancy testing Has an IUD or contraceptive implant (Implanon/Nexplanon) Critically ill, hemodynamically unstable, altered mental status, developmentally delayed, severe pain or distress, or have major trauma In juvenile justice custody


An 82-year-old woman comes to the emergency department because of chest pain and shortness of breath after being awakened in the morning by stabbing substernal chest pain radiating to the left shoulder and jaw. The patient had hypertension, renal-artery stenosis with chronic renal insufficiency, hypercholesterolemia, osteoporosis and dementia. Blood pressure was 199/108 mm Hg, respiratory rate 18 bpm, oxygen saturation 98% on ambient air. The heart sounds were rapid and with no murmurs. CK-MB was 10.9 ng/ml, CK was 89 U/l, CK index was 12.2% and Troponin T was 0.40 ng/ml. An EKG showed sinus regular tachycardia of 119 bpm, with ST-segment elevations up to 3 mm in V1, V2, and V3. A chest radiograph showed low lung volumes and right basilar subsegmental atelectasis. Coronary angiography showed no stenosis or clinically significant disease. Left ventriculography revealed akinesis of the anterior wall, hypokinesis of the apical and distal inferior walls, and compensatory hyperkinesis of the basal anterior and basal inferior walls. A transthoracic echocardiogram showed severe segmental left ventricular dysfunction involving the septum, anteroseptal territory, and apex. The overall left ventricular systolic function was mildly impaired and there was mild mitral regurgitation.

eligible ages (years): 18.0-999.0,  All  Atherosclerosis Cardiovascular Diseases Hypertension, Renovascular Renal Artery Obstruction Either Documented history of hypertension on two or more anti-hypertensive medications OR Renal dysfunction, defined as Stage 3 or greater chronic kidney disease (CKD) based on the new National Kidney Foundation (NKF) classifications (estimated glomerular filtration rate [GFR] less than 60 mL per minute per 1.73 m^2, calculated by the modified Modification of Diet in Renal Disease [MDRD] formula) One or more severe renal artery stenoses by any of the following pathways a. Angiographic: greater than or equal to 60% and less than 100% by renal angiogram OR b. Duplex: systolic velocity of greater than 300 cm/sec OR c. Core Lab approved Magnetic Resonance Angiogram (MRA) (refer to the protocol for specific criteria) demonstrating stenosis greater than 80% OR stenosis greater than 70% with spin dephasing on 3D phase contrast MRA OR stenosis greater than 70% and two of the following: i. Ischemic kidney is greater than 1 cm. smaller than contralateral kidney ii. Ischemic kidney enhances less on arterial phase iii. Ischemic kidney has delayed Gd excretion iv. Ischemic kidney hyper-concentrates the urine v. 2-D phase contrast flow waveform shows delayed systolic peak vi. Post-stenotic dilatation d. Clinical index of suspicion combined with a Core Lab approved Computed Tomography Angiography (CTA) demonstrating Stenosis is greater than 80% by visual assessment on high quality CTA Stenosis is greater than 70% on CTA by visual assessment and there are two of the following i. The length of the ischemic kidney is greater than 1 cm. smaller than contralateral kidney ii. Reduced cortical thickness of ischemic kidney iii. Less cortical enhancement of ischemic kidney on arterial phase iv. Post-stenotic dilatation  Unable to provide informed consent Unable or willing to comply with study protocol or procedures Must be greater than 18 years of age Fibromuscular dysplasia or other non-atherosclerotic renal artery stenosis known to be present prior to randomization Pregnancy or unknown pregnancy status in female of childbearing potential Participation in any drug or device trial during the study period, unless approved by the Steering Committee Prior enrollment in the CORAL study History of stroke within 6 months, if associated with a residual neurologic deficit* Any major surgery, major trauma, revascularization procedure, unstable angina, or myocardial infarction 30 days prior to study entry* Any planned major surgery or revascularization procedure, outside of the randomly allocated renal stenting indicated by the protocol, after randomization*


eligible ages (years): 10.0-16.0,  All  Heterozygous Familial Hypercholesterolemia Mixed Dyslipidemia 16 years old Heterozygous familial hypercholesterolemia  Homozygous familial hypercholesterolemia Pregnant or lactating females Major surgery during the six month prior study Other protocol defined and


eligible ages (years): 40.0-80.0,  All  COPD Criteria:Participants with COPD with an FEV1 of 80−30% predicted. This will incorporate the majority of participants with COPD seen within the chest clinic. Patients with an FEV1 > 80% predicted are not generally severe enough to warrant hospital follow up. These patients are also unlikely to have severe enough disease (and therefore airway inflammation) which may be modified by the therapeutic agents we are studying Patients with an FEV1 < 30% tend to have more severe symptom limitation and generally (though not always) find participation in a clinical trial involving 4 visits to the clinic difficult. Their airway disease is also generally less responsive to therapeutic intervention and as a consequence finding measurements which show changes to these therapeutic interventions is more difficult COPD patients All participants will be classified to Stage 2−3 of the GOLD (Global initiative for Obstructive Lung Disease) guidelines Male or female, aged 45-80 years (according to GOLD guidelines) < FEV1 < 80% predicted FEV1/FVC < 70% Cigarette exposure of >10 pack−years# With or without chronic symptoms (cough, sputum production, dyspnea) Steroid therapy will be stopped before run−in, but long acting bronchodilators are acceptable  Any history or evidence of asthma Pregnancy, breast−feeding or planned pregnancy during the study. Fertile women not using acceptable contraceptive measures, as judged by the investigator Hospital admission with respiratory infection within the last 6 months Upper respiratory infection within the last 4 weeks Participants who have received research medication within the previous one month Participants unable to give informed consent Any mental condition rendering the participant unable to understand the nature, scope and possible consequences of the study Known or suspected hypersensitivity to study therapy or excipients Participants with significant or unstable ischemic heart disease, arrhythmia, cardiomyopathy, heart failure, uncontrolled hypertension as defined by the investigator, or any other relevant cardiovascular disorder as judged by the investigator Any current respiratory tract disorders other than COPD, which is considered by the investigator to be clinically significant


eligible ages (years): 65.0-999.0,  All  Atrophy community living elderly females >/=65 years live expectation > 2 years  secondary osteoporosis CVD-events including stroke participation in other studies medication and illness affecting bone metabolism within the last 2 years medication with impact on falls low physical performance (<50 Watt during ergometry) excessive alcohol-intake


eligible ages (years): 18.0-80.0,  All  Coronary Artery Disease Acute Myocardial Infarction Age 18 to 80 Anterior myocardial infarction with Pathological Q-waves in at least 3 contiguous anterior precordial leads, assumed to be new CK peak>5 times the upper limit of normal with positive MB bands Ejection fraction <=40% or anterior dyskinesis or documented LV Thrombus MI onset < 7 days from randomization  Inability to give written informed consent Medical conditions that would prohibit discharge within 48 hours with the exception of need for anticoagulation Cardiogenic shock, rest angina unresponsive to medical therapy or serious ventricular arrhythmia in the 24 hours prior to randomization Patients scheduled for surgical procedure in the next 4 months that would prevent use of enoxaparin or warfarin Anemia: Baseline Hgb<=9 gm for women, <=10 gm for men or platelet count<100,000 Renal insufficiency (creatinine >2.0 mg/dl) Serious liver disease as reflected by INR>1.3 Stroke within past 6 months or a prior documented intracranial or subarachnoid hemorrhage Active bleeding or major surgery within 2 weeks prohibiting the use of anticoagulants Acute pericarditis


eligible ages (years): 30.0-80.0,  All  Acute Myocardial Infarction Patients will be eligible if presenting all characteristics described below ST segment elevation myocardial infarction, according to the WHO definition (two from the following three) i) Presence of chest pain. ii) Presence of ST segment elevation in two or more contiguous leads. iii) Elevation of the myonecrosis markers Age between 30 and 80 years old Invasive ventriculography presenting ejection fraction <50% (Dodge method) and segmentary dysfunction of the infarction area, measured immediately before PCI. Among patients submitted to thrombolytic therapy, the angioplasty of the related artery should be preferably done up to 24h after thrombolysis, with a maximum deadline of 48h after thrombolysis. This recommendation is based on the last Percutaneous Coronary Intervention guideline published by the European Society of Cardiology, in April 2005.68 IA recommendation degree  Patients will be ineligible if presenting any of the characteristics described below AMI related artery presenting TIMI < 3 at the moment f cell injection Left Main Coronary Artery Lesion of >50% or multivessel coronariopathy (>70% lesion in vessels with >2,0mm diameter in left anterior descending, circumflex and right coronary territory) indicating the need for CABG or angioplasty with three or more stents implant Coronary anatomy, after thrombolytic reperfusion, presenting no need for angioplasty with stent implant Final Diastolic Pression of the LV higher than 30 mmHg during ventriculography for evaluating EF for the research protocol (item "c" of criteria) Cardiac arrest or Killip IV AMI at admission with need of ventilatory support Cardiogenic shock persisting up to the third day after AMI (with need of Intra-aortic balloon pump or vasopressors) AMI mechanical complications (ventricular septal defect, papillary muscle rupture, and left ventricular free wall rupture) Significant valve disease, defined as aortic stenosis (mean systolic pressure gradient across the aortic valve >50mmHg), mitral stenosis with a valvar area less than 1,5 cm,2 moderate to severe aortic and/or mitral regurgitation Chronic use of immunosuppressive agents


eligible ages (years): 30.0-999.0,  All  Hypertension Atherosclerosis Every patient referred fo abdominal CT aged 30-100  Contraindication for IV contrast injection failure to demonstrate renal arteries with contrast refusal to sign an informed consent


eligible ages (years): 18.0-999.0,  All  Neuralgia Spinal Cord Injuries Subjects with nerve pain after Spinal cord injury (traumatic, diving, ischemic and after removal of benign tumors (except meningioma and fibromas) Pain has to be chronic(continuous for at least 3 months or intermittent for at least 6 months Pain score at least 4 in 4 of 7 days prior to receive treatment  Pregabalin use in the last 60 days, prior intolerance to pregabalin Creatinine clearance <60 mL/min White blood cell count <2500/mm3; neutrophil count <1500/mm3; platelet count <100 x 103/ mm3 Abuse of drugs or alcohol Unstable medial conditions Clinically significant abnormal electrocardiogram (ECG) Presence of severe pain associated with conditions other than spinal cord injury that could confound the assessment or self-evaluation of pain due to spinal cord injury


eligible ages (years): 18.0-75.0,  All  Acute Anterior Myocardial Infarction Each eligible patient must meet the following  Have ECG evidence of ongoing acute anterior myocardial infarction, involving a large area of myocardium, as defined by the following ECG a. Anterior infarct: ST-segment elevation >0.2mV measured 0.08 sec after the J point in 2 or more anatomically contiguous precordial leads, V1 through V4; and/or >0.2mV in lead V5 V6 Present to the RAPID MI-ICE site within six (6) hours of the onset of acute cardiac ischemic signs or symptoms (such as chest pain or pressure, arm or jaw pain, dyspnea, nausea/vomiting, or syncope) Be a candidate for PCI and have PCI planned as the immediate intervention Be willing and able to comply with study procedures, including returning for the MRI scan at 4 ±2 days and return for the clinical examination on Day 30 Provide written informed consent prior to the initiation of study-specific procedures Be in Killips Class I  Patients are not eligible for the study if they meet one or more of the following Age less than eighteen (<18) years of age Age greater than seventy-five (>75) years of age Are pregnant Have a suspected aortic dissection History of a prior anterior myocardial infarct or prior large myocardial infarct The suspected etiology of myocardial infarction is primarily related to substance abuse (e.g., cocaine, methamphetamine, etc.) Acute administration of a thrombolytic agent for the qualifying MI If (during the screening process) the determination is made by site-study personnel that initiation of cooling prior to diagnostic coronary angiography is technically not feasible for any reason (should the patient be randomized to the Hypothermia Arm), the prospective subject should not be enrolled Require an immediate surgical or procedural intervention other than PCI (e.g. CABG)


eligible ages (years): 18.0-999.0,  All  Myocardial Infarction Successful primary PCI (TIMI 2/3) for a first acute myocardial infarction, diagnosed by chest pain suggestive for acute myocardial infarction symptom onset < 12 hour before hospital admission, or < 24 hour in case ongoing ischemia ECG with ST-T segment elevation > 1 mV in 2 or more leads TIMI flow 0/1 before primary PCI on diagnostic coronary angiography  Hemoglobin levels > 10.6 mmol/L Anticipated additional revascularisation within 4 months Cardiogenic shock Presence of other serious medical conditions Pregnancy/breast feeding Malignant hypertension End stage renal failure (creatinin > 220 micromol/l) Previous treatment with rh-EPO Blood transfusion <12 weeks prior to randomisation Polycythemia vera


eligible ages (years): 65.0-999.0,  All  Dementia 65 years of age or older Diagnosed with dementia by a physician Mini-Mental State Examination score of 23 points or less Capable of participating at least once a week for 6 weeks in succession  Management of a medical risk required Impaired ability to pedal the ergometer because of an orthopedic or surgical disease of the lower extremities or central nerve paralysis Never having been on a bicycle, and incapable of pedaling well


eligible ages (years): 55.0-999.0,  All  Bone Loss Osteoporosis Breast Cancer elderly postmenopausal women (ages 55 and older) osteopenic (DXA T-score -1.0 to -2.5 SD). However, after full counseling about the risks, benefits, and options regarding therapy for osteoporosis and discussion with her PCP, an osteoporotic woman may enroll in the study with breast cancer on aromatase inhibitor therapy with no evidence of distant metastatic disease or osteoporosis (by BMD or clinical history) type of surgical procedure or addition of radiation therapy prior to this aromatase inhibitor therapy will not patients Participants must provide voluntary, written informed consent to participate in the study, which includes understanding of the procedures, medications, and risks and benefits  Women with stage 4 breast cancer (presence of distant metastases) Women with normal bone density by DXA (T-score > -1.0 SD)bone density by DXA, except in the instance of a fragility fracture Women with history of any illness known to affect bone and mineral metabolism, such as renal failure (estimated GFR <30), hepatic failure, malignancy (excluding breast cancer, treated superficial basal and squamous cell carcinoma and malignancies where the diagnosis itself or its treatment would not adversely affect bone metabolism), untreated primary hyperparathyroidism, and malabsorption Women being treated with oral glucocorticoid therapy >3 months for suppression therapy, and certain anti-seizure medications which may adversely affect bone metabolism (phenobarbital, phenytoin, carbamazepine) Those with untreated active peptic ulcer disease Those with osteoporosis by BMD (T-score -2.5 SD at the spine or total hip) or a history of fragility fracture as an adult. However, as discussed above, osteoporotic women may elect to enroll in the study Women treated with oral bisphosphonates or calcitonin for 3 months within the last year (3 month washout period) Men and children will be excluded because they do not get postmenopausal osteoporosis following treatment with an aromatase inhibitor Women with very poor dental hygiene (as assessed by the baseline dental exam) in need of dental extraction during the study Use of fluoride for more than 1 month ever (except for dental treatment)


eligible ages (years): 21.0-999.0,  All  Contrast Induced Nephropathy Age > 21 year Glomerular Filtration Rate (GFR) 15-60ml/min calculated by MDRD formula Scheduled to undergo elective PCI Able to receive 12 hours of pre-hydration Written informed consent  GFR less than 15ml/min or patients diagnosed with end stage renal failure Increase in serum creatinine levels of > 0.5mg/dl or 44umol/l in the previous 24 hours Preexisting dialysis Pulmonary edema or moderate to severe congestive heart failure (New York Heart Association [NYHA] III-IV) Patient unable to withstand the fluid load and hemodynamics compromise Uncontrolled hypertension (untreated systolic blood pressure > 160 mmHg, or diastolic blood pressure > 100mmHg.) Emergency cardiac catheterization (i.e. patient presenting with ST segment elevation myocardial infarction undergoing primary angioplasty) Recent exposure to radiographic contrast (within two days of the study) Allergic to radio-contrast


eligible ages (years): 18.0-75.0,  All  Cardiovascular Disease Signed informed consent to 75 years of age, inclusive Male or female Negative pregnancy test for women of child-bearing potential, or surgically sterile, or post menopausal Acute MI defined as Typical rise and gradual fall (troponin) or more rapid rise and fall (CK-MB) of biochemical markers of myocardial necrosis with at least one of the following Ischemic symptoms Development of pathologic Qwaves on the ECG ECG changes indicative of ischemia (ST segment elevation or depression) First anterior or inferolateral STEMI or Qwave MI (QMI Anterior: V1-V3 or V1-V4 or V1-V5 or V1-V6.QMI Inferior: L2, L3, AVF, or L2, L3, AVF+ V5, V6 or L2, L3, AVF+ V6-V9 [posterior leads])  History of CHF, Class I to Class IV, as per NYHA History of prior LV dysfunction At time of application of study device Killip III-IV (pulmonary edema, cardiogenic shock hypotension systolic < 90 mmHg and evidence of peripheral hypoperfusion oliguria, cyanosis, sweating) or HR > 100 bpm Prior CABG Prior MI History of stroke Significant valvular disease (moderate or severe) Patient is a candidate for CABG or PCI on non-IRA


eligible ages (years): 19.0-999.0,  All  Acute Renal Failure Male or female > or equal to 19 yrs of age ARF defined by at least one of the following Volume overload from inadequate urine output despite diuretic agents Oliguria (urine output < 200 ml/12hrs) despite fluid resuscitation and diuretic administration Anuria (urine output < 50 ml/12 hrs) Acute azotemia (BUN > or equal to 80 mg/dl) Acute hyperkalemia not responsive to medication (K+ > or equal to 6.5mmol/L) An increase in serum creatinine of > 2.5 mg/dl from normal values or a sustained rise in serum creatinine of > or equal to 1 mg/dl over baseline  Patients with end stage renal disease Patients who have had more than one previous dialysis session for acute or chronic renal failure during the current hospitalization Patient weight greater than 125 kg Patient weight less than 50 kg Pregnancy Prisoner Non-candidacy for continuous renal replacement therapy (CRRT) Patient/surrogate refusal


eligible ages (years): 18.0-999.0,  All  Cardiovascular Disease Men and women admitted for an IHD event (acute coronary syndrome or revascularization procedure) who are at low or moderate risk.91 Regular Internet access (home, work or other environment) Over 18 years of age Permission of the attending physician Able to read, write and understand English without difficulty No physical limitations to regular activity  Previous experience with a cardiac rehabilitation program Patients with depression, uncontrolled diabetes and other significant co-morbidities that may interfere with effective IHD management Those patients, who in the mind of the attending physician, are unsuitable for participation Those unable to provide informed consent Pregnant women High-risk patients for safety considerations (future studies will high-risk patients)


eligible ages (years): 18.0-999.0,  All  Ischemic Stroke Myocardial Ischemia Coronary Arteriosclerosis Age ≥ 18 years old Symptoms suggestive of an acute ischemic stroke Informed consent  Present intracerebral or subarachnoid haemorrhage Present intracerebral vascular malformation Present transient ischemic attack Prior coronary bypass surgery or percutaneous coronary intervention Pacemaker Allergy to contrast Lack of cooperation


eligible ages (years): 18.0-999.0,  All  Primary Hypercholesterolemia Homozygous Familial Hypercholesterolemia Outpatient men or women, age 18 years and above Patients with primary (heterozygous familial and non-familial) hypercholesterolemia or homozygous familial hypercholesterolemia  Known hypersensitivity to Ezetimibe Moderate to severe hepatic insufficiency Persistent elevation of serum transaminase levels of more than 1.5 times the upper limit of normal Pregnancy or lactation Concomitant intake of bile acid sequestrants (resins), nicotinic acid (niacin), fibric acid (fibrates), or cyclosporine


eligible ages (years): 18.0-999.0,  All  Renal Artery Stenosis PAD and unilateral ostial >60% RAS and hypertension  Conditions which imply RAS stenting (bilateral significant renal disease, single functioning kidney, or patients whose conditions cannot be managed medically or by intervention) Allergy to contrast agents or medication administered for best medical treatment (in particular ASA and statins)


eligible ages (years): 30.0-80.0,  All  Myocardial Infarction First anterior myocardial infarction Low systolic ventricular function  Bleeding tendency Contraindication to G-CSF Cardiogenic shock Hemodynamic instability Hepatic or renal disease Multivessel disease


eligible ages (years): 18.0-999.0,  All  Hyperplasia Restenosis Patients must meet all of the following The patient must be > 18 years of age Diagnosis of stable angina pectoris as defined by Canadian Cardiovascular Society Classification (CCS I, II, III, IV) or ACS (except STEMI) Treatment of de novo lesion in a major coronary artery in patients with single or two-vessel disease Target vessel diameter at the lesion site is >2.50mm and <3.50mm in diameter (QCA) Target lesion is >10mm and <24mm in length (visual estimate) Target lesion stenosis is >50% and <100% (visual estimate) Acceptable candidate for coronary artery bypass surgery (CABG) Patient is willing to comply with the specified follow-up evaluation Patient must provide written informed consent prior to the procedure using a form that is approved by the local Ethics Committee  Patients will be excluded if any of the following conditions apply multiple lesions in the same vessel ACS with STEMI (within 48 hours) vessel size < 2.50mm and >3.50mm reference diameter length of the lesion > 24 mm unprotected left main coronary disease with >50% stenosis have an ostial target lesion have a target lesion in a venous graft angiographic evidence of thrombus within target lesion calcified lesion which cannot be successfully predilated


eligible ages (years): 50.0-999.0,  All  Cataract Subjects must have a clinically documented diagnosis of age-related cataract Subjects must have clear intraocular media other than cataract Subjects must be undergoing primary in-the-bag intraocular lens implantation for the correction of aphakia following continuous curvilinear anterior capsulotomy and phacoemulsification cataract extraction  Subjects with any anterior segment pathology for which extracapsular phacoemulsification cataract surgery would be contraindicated Subjects with diagnosis of degenerative visual disorder Subjects who have any inflammation or edema (swelling) of the cornea Subjects with immunodeficiency disorders Subjects who have had previous intraocular surgery in the study eye Subjects with incomplete/damaged zonule, or with conditions associated with increased risk of zonular rupture Subjects with chronic use of systemic steroids or immunosuppressive medications


eligible ages (years): 18.0-65.0,  All  Obesity, Morbid Ischemic Heart Disease Morbidly obese patients who fulfill the NIH for surgical intervention  Patients deemed unfit for surgery Pregnant women, or who are attempting conception Subjects with any history of myocardial infarction, coronary artery bypass grafting surgery, coronary angiography with angioplasty and/or stenting, or any lesion > 50% of the coronary artery luminal diameter, cerebrovascular accident, or peripheral vascular disease with abnormal electrocardiograms and/or echocardiography History of drug or alcohol abuse Chronic liver disease


eligible ages (years): 18.0-999.0,  All  Hyponatremia Acute Decompensated Heart Failure Presents to emergency department with documented history of CHF and symptomatic ADHF, will be treated for ADHF, and primary reason for admission to the hospital is ADHF Dyspnea at rest or with minimal exertion and must have moderate shortness of breath (SOB) in any of the first three Provocative Dyspnea Assessment positions Severe pulmonary congestion as evidenced by jugular venous distention or lower extremity/sacral edema or rales upon chest auscultation or chest x-ray BNP > 400 or NT-pro BNP > 1500 drawn during Screening Systolic blood pressure >= 100 mmHg to < 180 mmHg at time of start of study drug Serum sodium value >= 115 mEq/L (115 mmol/L) and < 135 mEq/L (135 mmol/L) during Screening  Clinical evidence of volume depletion Active ongoing acute coronary syndrome or acute ST segment elevation myocardial infarction (or has experienced a myocardial infarction within 30 days of Screening) In cardiogenic shock Calculated creatinine clearance < 30 mL/min/1.73 m2 as estimated by the Modification of Diet in Renal Disease (MDRD) equation, has received intravenous (IV) contrast agent within 72 hours prior to randomization or is expected to receive IV contrast agent within the first 72 hours of study participation Ultrafiltration within the past 72 hours Currently using or expected to use inotropic therapy Cardiac bypass grafts in the past 60 days Cerebrovascular accident in the past 30 days Uncontrolled brady or ventricular tachyarrhythmias requiring emergent pacemaker placement or treatment


eligible ages (years): 18.0-999.0,  All  Acute Coronary Syndrome typical chest pain ST segment elevation or depression in ECG indication for coronary angiography; if necessary with PCI and 4) signed inform consent  known past history of a myocardial infarction not signed informed consent


eligible ages (years): 18.0-999.0,  All  Hypercholesterolemia Outpatient men or women, age 18 years and above Patients with primary (heterozygous familial and non-familial) hypercholesterolemia  Known hypersensitivity to Ezetimibe and Simvastatin Moderate to severe hepatic insufficiency Persistent elevation of serum transaminase levels of more than 1.5 times the upper limit of normal Pregnancy or lactation Concomitant intake of bile acid sequestrants (resins), nicotinic acid (niacin), fibric acid (fibrates), or cyclosporine


eligible ages (years): 18.0-80.0,  All  Ventricular Tachycardia Coronary Artery Disease Left Ventricular Dysfunction Coronary artery disease For the purpose of this study, coronary artery disease will be defined as the presence of a 50 % or more diameter stenosis of the left main coronary artery, or 75 % or more diameter stenosis of the left anterior descending, circumflex or right coronary arteries, or the history of a surgical or percutaneous revascularization procedure, or history of successful thrombolysis, or a history of prior myocardial infarction (e.g.: documented by Q-wave, R-reduction, aneurysm) Left ventricular ejection fraction ≤ 50 % as estimated by echocardiography or contrast ventriculography within the previous 30 days and evidence for old myocardial infarction (ECG, echocardiographic or venticulographic) One episode of documented stable clinical VT without any reversible causes Written informed consent  Age < 18 years or > 80 year Protruding LV thrombus on pre-ablation echocardiogram Acute myocardial infarction within the preceding 1 months Class IV NYHA heart failure Valvular heart disease or mechanical heart valve precluding access to the left ventricle Unstable angina Cardiac surgery involving cardiotomy (not CABG) within the past 2 months Serum creatinine > 220 mmol/L (2.5 mg/dL) Thrombocytopenia or coagulopathy Contraindication to heparin


eligible ages (years): 2.0-90.0,  All  Aged elderly subjects over the age 65 years who had not received pneumococcal vaccination adult subjects under the age of 45 years (healthy volunteers with no previous history of pneumococcal vaccination) children subjects over the age of 2 years with no previous history of pneumococcal vaccination  immunocompromised, asplenia, cancer, liver or renal failure, and history of hypersensitivity to vaccine


eligible ages (years): 18.0-999.0,  All  Acute Coronary Syndrome Myocardial Infarction Unstable Angina Pectoris Patients with any episode > five minutes of chest pain being admitted to rule out acute coronary syndrome  Positive initial troponin or CK-MB tests Diagnostic ECG changes (ST segment elevation or horizontal ST segment depression in more than two contiguous leads) Unstable clinical condition (hemodynamically unstable, ventricular tachycardia, persistent chest pain despite adequate therapy) Creatinine Clearance <50 mL/min Known allergy to iodinated contrast agents Patients on metformin therapy unable or unwilling to discontinue therapy for 48 hours after CT scan procedure Known asthma, reactive airway disease Patients currently in atrial fibrillation


eligible ages (years): 18.0-999.0,  All  Myocardial Reperfusion Injury clinical evidence of myocardial infarction defined by the presence of ischemic chest pain lasting more than 30 minutes, with a time interval from the onset of symptoms less than 6 hours before hospital admission, associated with typical ST-segment elevation on the 12-lead ECG angiographic-detected culprit lesion with stenosis diameter >70% and TIMI flow grade <=1  previous acute myocardial infarction previous myocardial revascularization (angioplasty or coronary bypass) previous heart valve replacement previous heart transplant clinical instability precluding the suitability of the study cardiogenic shock or persistent hypotension (systolic blood pressure <100 mmHg) rescue angioplasty after thrombolytic therapy evidence of coronary collaterals (Rentrop grade>0) in the risk area advanced atrioventricular block significant bradycardia


eligible ages (years): 18.0-75.0,  All  Cocaine Dependence meet DSM-IV for lifetime cocaine dependence and have used cocaine in the prior 6 months be > 18 years of age be judged clinically appropriate for IOP (e.g., no current psychotic disorder or evidence of severe dementia, and no acute medical problem requiring inpatient treatment have no regular IV heroin use during the past year have access to a telephone be willing to be randomized and participate in research; and no current participation in methadone or other forms of DA treatment, other than IOP. Finally, because of study follow-up requirements, subjects will be required to be metropolitan area residents, and be able to provide the name, verified telephone number, and address of at least two contacts who can provide locator information on the patient during follow-up. We will patients with dependence on other substances, provided that they are cocaine dependent and meet other criteria  have a current psychotic disorder (as assessed with the psychotic screen from the MINI) or evidence of dementia severe enough to prevent participation in outpatient treatment have acute medical problem requiring immediate inpatient treatment; or are currently participating in methadone or other forms of DA treatment, other than IOP


eligible ages (years): 19.0-999.0,  All  Cardiovascular Risk Factors Age ≥ 65 years Hypertension (HTN) Diabetes Obesity (body mass index [BMI] >35) Renal insufficiency Tobacco usage Hypercholesterolemia Sleep apnea/heavy snoring at night Clinical diagnosis of CHF as defined by Dyspnea on exertion  Patients expected to say in the hospital for less than 24 hours Inability of undergo TEE and TTE Clinical evidence or suspicion of elevated intracranial pressure Preoperative shock or systemic sepsis Emergency Operation ASA Class V Inability of give informed consent Participation in another clinical trial Prisoner


eligible ages (years): 10.0-999.0,  All  Primary Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH) Participants Who Receives Vytorin In Usual Medical Practice Within Local Label For The First Time


eligible ages (years): 70.0-999.0,  All  Mild Dementia elderly (> 70 years) with mild dementia in presence of a carer


eligible ages (years): 40.0-75.0,  All  Acute Coronary Syndrome Myocardial Infarction Unstable Angina Pectoris Participant had at least five minutes of chest pain or equivalent (chest tightness; pain radiating to left, right, or both arms or shoulders, back, neck, epigastrium, jaw/throat; or unexplained shortness of breath, syncope/presyncope, generalized weakness, nausea, or vomiting thought to be of cardiac origin) at rest or during exercise within 24 hours of ED presentation, warranting further risk stratification, as determined by an ED attending 2 or more cardiac risk factors (diabetes, hypertension, hyperlipidemia, current smoker and family history of coronary artery disease) Able to provide a written informed consent <75 years of age, but >40 years of age Able to hold breath for at least 10 seconds Sinus rhythm  New diagnostic ischemic ECG changes (ST-segment elevation or depression > 1 mm or T-wave inversion > 4 mm) in more than two anatomically adjacent leads or left bundle branch block Documented or self-reported history of CAD (MI, percutaneous coronary interventions [PCIs], coronary artery bypass graft [CABG], known significant coronary stenosis [>50%]) Greater than 6 hours since presentation to ED BMI >40 kg/m2 Impaired renal function as defined by serum creatinine >1.5 mg/dL* Elevated troponin-T (> 0.09 ng/ml) Hemodynamically or clinically unstable condition (BP systolic < 80 mm Hg, atrial or ventricular arrhythmias, persistent chest pain despite adequate therapy) Known allergy to iodinated contrast agent Currently symptomatic asthma Documented or self-reported cocaine use within the past 48 hours (acute)


eligible ages (years): 18.0-999.0,  All  Diabetes Mellitus, Type 2 years of age or older Newly prescribed Saxagliptin or an OAD in a class other than DPP4 inhibitors Enrolled in the respective database for at least 180 days prior to the first prescription for Saxagliptin or other OAD in a class other than DPP4 inhibitors  Patients identified with a diagnostic code for any of the cardiovascular outcomes of interest within the 180-day baseline period Patients prescribed a DPP4 inhibitor during the baseline period


eligible ages (years): 65.0-999.0,  All  Distal Radius Fracture All patients older than 65 years old with an acute DRF were considered for for this study. criterion of this study was an unacceptable closed reduction after one attempt of closed reduction. The of unacceptable closed reduction included dorsal angulation of > 100, volar angulation of > 200, an articular gap or step off of >2 mm, radial inclination of <100, or radial shortening of > 5mm  A preexisting severe illness An ipsilateral upper extremity injury A previous wrist injury Surgical delay of more than 2 weeks A concomitant ulnar neck fracture


eligible ages (years): 0.0-999.0,  All  Hypertension Angina Pectoris Hypercholesterolemia Familial Hypercholesterolemia Male or Female subjects intend to treat their cardiovascular disease who are prescribed Amlodipine /Atorvastatin (Caduet®) Combination Tablets by their Physicians  Subjects who have been prescribed Amlodipine /Atorvastatin (Caduet®) Combination Tablets before


eligible ages (years): 20.0-999.0,  All  Vascular Disease Myocardial Ischemia Coronary Artery Stenosis Coronary Disease Coronary Artery Disease Coronary Restenosis Subject must be at least 20 years of age Subject or a legally authorized representative must provide written informed consent prior to any study related procedure, per site requirements Subject must have evidence of myocardial ischemia (e.g., stable or unstable angina, silent ischemia, positive functional study or a reversible change in the electrocardiogram (ECG) consistent with ischemia) Subject must be an acceptable candidate for coronary artery bypass graft (CABG) surgery Subject must agree to undergo all protocol-required follow-up procedures Subject must agree not to participate in any other clinical study for a period of one year following the index procedure Angiographic One (target) or two (one target and one non-target) de novo lesions each in a different epicardial vessel Lesion(s) must be located in a major artery or branch with a visually estimated diameter stenosis of ≥ 50% and < 100% with a TIMI flow of ≥ 1 Lesion(s) must be located in a native coronary artery with reference vessel diameter (RVD) by visual estimation of ≥ 2.25 mm and < 2.5 mm  Subject has had a known diagnosis of acute myocardial infarction (AMI) preceding the index procedure (CK-MB ≥ 2 times upper limit of normal) and CK and CK-MB have not returned to within normal limits at the time of procedure The subject is currently experiencing clinical symptoms consistent with new onset AMI, such as nitrate-unresponsive prolonged chest pain with ischemic ECG changes Subject has current unstable cardiac arrhythmias associated with hemodynamic instability Subject has a known left ventricular ejection fraction (LVEF) < 40% (LVEF may be obtained at the time of the index procedure if the value is unknown and if necessary) Subject has received coronary brachytherapy in any epicardial vessel Subject has received any organ transplant or is on a waiting list for any organ transplant Subject is receiving or scheduled to receive chemotherapy for malignancy within 30 days prior to or within one year after the index procedure Subject is receiving or scheduled to receive planned radiotherapy to the chest/mediastinum Subject is receiving immunosuppressant therapy or has known immunosuppressive or autoimmune disease (e.g. human immunodeficiency virus, systemic lupus erythematosus etc.) Subject is receiving chronic anticoagulation therapy (e.g., heparin, warfarin)


eligible ages (years): 18.0-75.0,  All  Renal Artery Stenosis Hypertension At least moderate (60% or more) renal artery stenosis with atheromatic appearance in angiography Hypertension defined according to WHO Age 18-75 years Signed informed consent obtained  Bilateral renal artery stenosis or significant renal artery stenosis in solitary kidney Contraindications to percutaneous renal angioplasty with stenting Atrophy of the kidney supplied with stenosed artery Other well known secondary reason for hypertension Chronic heart failure NYHA II-IV Significant valvular heart disease qualified for surgery Persistent atrial fibrillation Renal failure with GFR below 30ml/min


eligible ages (years): 0.0-999.0,  All  Mitral Valve Insufficiency Atrial Fibrillation Heart Failure Patients with severe mitral regurgitation are admitted for surgical intervention and are willing to participate in this study  Presence of mitral stenosis More than mild severity of aortic valvular problem Any abnormality of atrial septum (e.g., atrial septal defect or aneurysm) Rhythm other than sinus rhythm Inadequate image quality Lack of informed consent


eligible ages (years): 18.0-85.0,  All  Renal Artery Stenosis Left Ventricular Hypertrophy ischemic heart disease angiographic diagnosis of atherosclerotic RAS >50% and ≤80%  Atherosclerotic RAS>80% RAS secondary to fibromuscular dysplasia AMI single functioning kidney and/or sCr >4 mg/dl severe aortic valve stenosis aortic aneurism necessitating surgery


eligible ages (years): 18.0-999.0,  All  Chronic Coronary Occlusion Unprotected Left Main Coronary Artery Disease Stent Thrombosis Vascular Disease Myocardial Ischemia Coronary Artery Stenosis Coronary Disease Coronary Artery Disease Coronary Restenosis * for RCT Unprotected left main coronary artery (ULMCA) disease with angiographic diameter stenosis (DS) ≥70% requiring revascularization, or ULMCA disease with angiographic DS ≥50% but <70% requiring revascularization, or Left Main Equivalent Disease Clinical and anatomic for both PCI and CABG Silent ischemia, stable angina, unstable angina or recent MI Ability to sign informed consent and comply with all study procedures including follow-up for at least three years  * Clinical Prior PCI of the left main trunk at any time prior to randomization Prior PCI of any other coronary artery lesions within one year prior to randomization Prior CABG at any time prior to randomization Need for any concomitant cardiac surgery other than CABG, or intent that if the subject randomizes to surgery, any cardiac surgical procedure other than isolated CABG will be performed Any recent MI with CK-MB levels still elevated Subjects unable to tolerate, obtain or comply with dual antiplatelet therapy for at least one year Subjects requiring or who may require additional surgery within one year The presence of any clinical condition(s) which leads the participating interventional cardiologist to believe that clinical equipoise is not present The presence of any clinical condition(s) which leads the participating cardiac surgeon to believe that clinical equipoise is not present


eligible ages (years): 18.0-999.0,  All  Hypercholesterolemia Patients with hypercholesterolemia currently receiving a lipid lowering agent  Pregnancy and lactation


eligible ages (years): 18.0-999.0,  All  Renal Artery Stenosis RAS affecting the main renal artery or its major branches at angio-CT either > 70% or, if < 70 with post-stenotic dilatation AND resistance index (RI) < 0.55 or > 0.55 but < 0.80 with evidence of intrarenal heterogeneity of the RI as revealed by a CV > 10% in the RI across the upper, mid and lower third of each kidney  refusal to participate to study previous endovascular or surgical treatment of RAS fibromuscular RAS planned or actual pregnancy, or childbearing potential without measures adequate to prevent pregnancy life expectancy < 2 years patient currently participating in another trial possibly influencing the safety of the patient and/or the outcomes of the study co-morbid conditions limiting participation and follow-up


eligible ages (years): 65.0-80.0,  All  Osteoporosis women from 65 to 80 yrs of age diagnosis of osteoporosis classified according to the of the World Health Organization, with bone mineral densitometry reduced by at least 2.5 SD when compared with young adults (region of lumbar spine)  severe visual deficiency physically incapable of participating in the tests neurological disorders, amputations, or prostheses individuals with regular physical activity (twice or more per week) or who had recently participated in exercise programs for muscular strength or balance


eligible ages (years): 18.0-999.0,  All  Hypercholesterolemia Patients on lipid lowering drug treatment Lipid lowering drug treatment lasting at least 3 months No lipid lowering drug/dose change for a minimum 6 weeks prior to enrolment to the study  Lack of patient's signed informed consent form Lack of the blood sample taken for lipid profile and glucose within 10 days before or after assessment of the patient


eligible ages (years): 50.0-999.0,  All  Type 2 Diabetes, Hispanic/Latinos, Diabetes Self-management Education Self-identification as Hispanic/Latino, over the age of 18 years of age, diagnosis of type 2 diabetes and willingness to participate in the diabetes self-management education class  non-diabetic persons, non English-speaking Hispanic/Latinos with type 2 diabetes


eligible ages (years): 0.0-70.0,  All  Ischemic Heart Disease Obesity obesity Ischemic Heart disease Signed informed consent  Visual or manual limitations that preclude reading and writing Unwilling to participate


eligible ages (years): 18.0-999.0,  All  Heart Failure Coronary Artery Disease Ischemic Cardiomyopathy Non-ischemic Cardiomyopathy Age >18 years Known or highly suspected coronary artery disease (CAD) documented by coronary angiography or by history of previous MI or evidence of moderate ischemia or scar based on prior imaging LV dysfunction most likely attributable to ischemic heart disease with EF <45% measured by any acceptable means (echo, nuclear RNA, PET or SPECT perfusion, Angiography, Cardiac MR) within the previous 6 months AND NYHA class II-IV symptoms within the past 12 months LV dysfunction most likely attributable to ischemic heart disease with EF ≤30% measured by any acceptable means (echo, nuclear RNA, PET or SPECT perfusion, Angiography, Cardiac MR) within the previous 6 months AND NYHA class I within the past 12 months  Severe medical conditions that significantly affect the patient's outcome (eg. severe COPD, active metastatic malignancy) and would preclude revascularization < 4 weeks post ST segment elevation myocardial infarction (STEMI) Already identified as not suitable for revascularization Emergency revascularization indicated Severe valvular heart disease requiring surgery Contraindications to CMR (eg metallic implant, claustrophobia, renal failure (GFR <30 ml/min/1.73m2),). However patients with permanent pacemakers or implanted defibrillators or GFR <30 ml/min/1.7m2, will be randomized only to standard imaging (SPECT) versus PET or entered into the registry if only 1 modality is available Pregnancy Potential for non compliance to tests involved in this protocol Incapacity to provide informed consent


eligible ages (years): 18.0-999.0,  All  Coronary Disease Coronary Artery Disease Coronary Artery Stenosis Coronary Artery Restenosis Patient must be at least 18 years of age Patient is able to verbally confirm understanding of risks, benefits and treatment alternatives of receiving the V® EECSS and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure, as approved by the appropriate Medical Ethics Committee of the respective clinical site Patient has been diagnosed a MVD, as documented by coronary angiography, i.e. presenting a severe stenosis (>50%) amenable to PCI in at least 2 major epicardial vessels or their principal bifurcation branches (diagonal or obtuse marginal) Patient must have evidence of myocardial ischemia (e.g., stable or unstable angina, silent ischemia, positive functional study or a reversible change in the electrocardiogram -ECG consistent with ischemia) Patient must be an acceptable candidate for coronary artery bypass graft (CABG) surgery Patient must agree to undergo all protocol-required follow-up examinations Angiographic Patients may receive up to 4 planned V® EECSS stents, depending on the number of vessels treated and their respective lesion length. When multiple lesions are present in one or more main coronary branches, complete revascularization should be attempted with the implantation of a maximum of 4 planned stents Target lesions must be de novo lesions (no prior stent implant, no prior brachytherapy)  Patient has had a known diagnosis of acute myocardial infarction (AMI) within 72 hours preceding the index procedure (non-procedural/spontaneous MI, CK-MB > or = to 2 times upper limit of normal) and CK and CK-MB have not returned within normal limits at the time of procedure Patient has current unstable arrhythmias Patient has a known left ventricular ejection fraction (LVEF) <30% Patient has received a heart transplant or any other organ transplant or is on a waiting list for any organ transplant Patient is receiving or scheduled to receive chemotherapy or radiation therapy within 30 days prior to or after the procedure Patient is receiving immunosuppression therapy or has known immunosuppressive or autoimmune disease (e.g. human immunodeficiency virus, systemic lupus erythematosus etc.) Patient is receiving chronic anticoagulation therapy (e.g. coumadin) Patient has a known hypersensitivity or contraindication to aspirin, paclitaxel, either heparin or bivalirudin, clopidogrel or ticlopidine, everolimus, cobalt, chromium, nickel, tungsten, acrylic and fluoro polymers or contrast sensitivity that cannot be adequately pre-medicated Elective surgery is planned within the first 9 months (+/ days) after the procedure that will require discontinuing either aspirin or clopidogrel


eligible ages (years): 75.0-999.0,  All  the Elderly of 75 Years and Older Living at Home years of age and older man or woman Patient covered by the health care system Patient coverd by a complementary health system or supported by 100% by the health care system Patient having the intellectual skills to understand the study, to respect its imperatives and accept the UPSAV's plan or subject with mild to moderate dementia (MMSE > 10) but with a caregiver at home capable of understanding the protocol and of making respect its imperatives written consent signed by the patient  Nursing-home resident Mild to moderate dementia (MMSE > 10) without caregiver Severe dementia (MMSE < 10) Diseases with vital short-term endpoint


eligible ages (years): 18.0-85.0,  All  Myocardial Infarction Multivessel Coronary Artery Disease All patients between 18-85 years presenting with STEMI who will be treated with primary PCI in < 12 h after the onset of symptoms* and have at least one stenosis of >50% in a non-IRA on QCA or visual estimation of baseline angiography and judged feasible for treatment with PCI by the operator Patients with symptoms for more than 12 hr but ongoing angina complaints can be randomised  Left main stem disease (stenosis > 50%) STEMI due to in-stent thrombosis Chronic total occlusion of a non-IRA Severe stenosis with TIMI flow ≤ II of the non-IRA artery Non-IRA stenosis not amenable for PCI treatment (operators decision) Complicated IRA treatment, with one or more of the following Extravasation Permanent no re-flow after IRA treatment (TIMI flow 0-1) Inability to implant a stent Known severe cardiac valve dysfunction that will require surgery in the follow-up period


eligible ages (years): 18.0-999.0,  All  Heart Failure Men and women age 18 or older referred for invasive evaluation of possible renal artery stenosis will be screened for enrollment Patients must be inpatients admitted for heart failure exacerbation, or have been admitted to a hospital for heart failure exacerbation within the past 90 days. Heart failure is defined as physician documentation or report of any of the following clinical symptoms of heart failure described as dyspnea on exertion, dyspnea occurring in the supine position, fluid retention; or the description of rales, jugular venous distension, pulmonary edema on physical exam, or pulmonary edema on chest x-ray; without being clearly attributable to liver, kidney, or lung disease. Patients must have one of the following: 1. an ejection fraction of 50%; 2. an ejection fraction of 25-50% in the setting of a systolic blood pressure of at least 160 mmHg; or 3. an ejection fraction of 25-50% and a systolic blood pressure of at least 140 mmHg while being treated with at least 2 antihypertensive medications. Patients who meet these and have a proven hemodynamically significant renal artery stenosis (as described in the procedure section) will be included  Patients with heart failure from structural heart disease (including greater than moderate dysfunction of the mitral or aortic valve), acute coronary syndrome, post-partum cardiomyopathy, or acute rejection of a transplanted heart will be excluded. Patients who are considered unlikely to survive to hospital discharge will be excluded. Patients with fibromuscular dysplasia, prior renal stenting, or anatomy unsuitable for renal stenting (i.e. prior vascular surgery making stent delivery impossible) will be excluded. Patients who are unable to take aspirin and clopidogrel will be excluded. Patients with a creatinine clearance <30 mL/min or a history of renal transplantation will be excluded. Pregnant women will be excluded


eligible ages (years): 60.0-999.0,  All  Femoral Neck Fracture Age of 60 years or more, ambulatory with/without walking aids before trauma Femoral neck fracture eligible for hemi-arthroplasty in accordance with the algorithm for femoral neck fracture patients used at the University hospital Basel Informed consent  Refusal of consent by the patient or legal representatives to participate in the study More than one fracture Suspicion of a pathological fracture in the context of known or unknown malignancy Previous surgery of the proximal femur on the same side Follow-up not possible (Tourist etc.)


eligible ages (years): 18.0-999.0,  All  Myocardial Infarction History of anterior MI within the prior 4 weeks to 12 months due to coronary artery atherosclerotic disease and evidenced by typical ischemic symptoms, serial ST-T changes (new ST elevation or new left bundle block) and elevated troponin or CK-MB >5 times the upper limit of normal with at least one of the following, based on standardly accepted definition of acute MI: development of pathological Q wave ECG changes, imaging evidence of new loss of viable myocardium, or new regional wall motion abnormalities History of percutaneous coronary intervention (PCI), with stent placement resulting in TIMI flow = 3, in the left anterior descending coronary artery supplying the infarcted, dysfunctional territory and through which the treatment will be infused At least one historical assessment of left ventricular ejection function (LVEF) ≤0.45 as determined by any one of the standard modalities (echocardiography, ventriculogram, nuclear imaging, CT and/or MRI). For subjects that fulfill the of Recent MI (i.e., within 90 days of MI) at time of screening visit: assessment must be post-reperfusion after index MI and be the most recent test prior to signing informed consent. For subjects that fulfill the of Chronic MI (i.e., greater than 90 days from MI) at time of screening visit: assessment must be at least 21 days post-reperfusion after index MI and the most recent test prior to signing informed consent. Note: subjects may screen as a Recent MI but be randomized into the Chronic MI strata if the infusion date is > 90 days post-MI Left ventricular infarct size of ≥ 15% of left ventricular mass as determined by screening MRI, with associated thinning and/or hypokinesis, akinesis, or dyskinesis, with no large aneurysmal area in the anterior/anterolateral/anteroseptal regions . In subjects with infarcts in >1 myocardial wall, >50% of the total LV scar should be in the anterior/anterolateral/anteroseptal regions No further revascularization clinically indicated at the time the subject is assessed for participation in the clinical trial Ability to provide informed consent and follow-up with protocol procedures Age ≥18 years  Subjects with a history of coronary artery bypass surgery, and a graft (left internal mammary artery or saphenous vein graft) attached to the left anterior descending coronary artery Diagnosed or suspected myocarditis History of cardiac tumor, or cardiac tumor demonstrated on screening MRI History of acute coronary syndrome in the 4 weeks prior to study infusion History of previous stem cell therapy History of radiation treatment to the central or left side of thorax Current or history (within the previous 5 years) of systematic auto-immune or connective tissue disease including, but not limited to, giant cell myocarditis, cardiac or systemic sarcoidosis, Dressler's syndrome, chronic, recurrent or persistent pericarditis History of or current treatment with immunosuppressive, anti-inflammatory, or other agents to treat manifestations of systemic immunologic reactions, including chronic systemic corticosteroids, biologic agents targeting the immune system, anti-tumor and anti-neoplastic drugs, anti-VEGF, or chemotherapeutic agents within 3 months prior to enrollment Prior of planned ICD and/or pacemaker placement Estimated glomerular filtration rate < 30 mL/min


eligible ages (years): 18.0-30.0,  All  Osteoporosis Participants young and healthy women between the ages of 18-30, who have not engaged in strength training for the last 6 months  Subjects will be excluded from the study if they have any condition that preclude them from taking part in the exercise testing procedures or the 24 week exercise program or if they fail to obtain the required amount of training sessions


eligible ages (years): 45.0-999.0,  All  Chest Pain Shortness of Breath Suspected Acute Coronary Syndrome Patients with chest pain or SOB admitted for rule out acute coronary syndrome Age ≥45 years EKG non-diagnostic for acute coronary syndrome At least 1 set of negative troponin I  Patient with ST elevation myocardial infarction Patients with non-ST elevation myocardial infarction Patients with known CAD Patients with serum creatinine > 1.5 Atrial fibrillation or marked irregular heart rhythm Patients in whom heart rate cannot be controlled Patient with allergies to iodinated contrast agents Pregnant women Patients unable to give informed consent


eligible ages (years): 18.0-999.0,  All  Acute Coronary Syndrome Non-ST-segment elevation ACS patients [ischemic symptoms suspicious of non-ST-segment elevation ACS (unstable angina or non-ST-segment elevation AMI) defined as clinical presentation compatible with a new manifestation of worsening of chest pain characteristic of ischemia, at rest or at minimum effort, lasting more than 10 minutes, and at least one of the following items: (a) ECG changes compatible with new ischemia (ST segment depression of at least 1 mm, or transient ST segment elevation, or ST segment elevation ≤ 1 mm, or T wave inversion > 2 mm in at least 2 contiguous shunts); (b) cardiac enzymes (CK-MB or troponin T or I) above the upper normality range limit; (c) patients > 60 years of age without ECG or myocardial necrosis markers changes, however with previous documentation of coronary atherosclerotic disease (CAD), confirmed by previous hospitalization due to AMI, previous percutaneous or surgical myocardial revascularization procedure, significant CAD confirmed by coronary angiography, or positive functional test for myocardial ischemia] Intention to submit patient to early invasive strategy consisting of coronary angiography immediately followed by PCI, when applicable, in the first 72 hours after admission Signed informed consent Patient eligible for transradial and transfemoral coronary angiography and PCI, being pre-requisites: (a) palpable radial artery with normal Allen test or/and oximetry tests, (b) familiarity of the operator with the radial and femoral techniques using AngioSeal, (c) agreement of the operator to use the access route determined by the randomization process  Less than 18 years of age Pregnancy Chronic use of vitamin K antagonists or direct thrombin inhibitors, or oral Xa-factor antagonists Hypersensitivity to antiplatelet and/or anticoagulant drugs Active bleeding or high bleeding risk (severe liver failure, active peptic ulcer, creatinine clearance < 30 mL/min, platelets count < 100.000 mm3) Uncontrolled systemic hypertension Cardiogenic shock Previous myocardial revascularization surgery with ≥ 1 internal mammary or radial artery graft Documented chronic peripheral arterial disease preventing the use of the femoral technique Severe concomitant disease with life expectancy below 12 months


eligible ages (years): 18.0-999.0,  All  Renal Artery Stenosis Hypertension, Renovascular General Age ≥ 18 at the time of informed consent Subject or subject's legal representative have been informed of the nature of the trial, agrees to participate, and has signed an Institutional Review Board (IRB)/Ethics Committee (EC) approved Informed Consent Form (ICF) Subjects that have bilateral kidneys or a solitary functioning kidney with Renal Artery Stenosis in at least one kidney and an average Systolic Blood Pressure (SBP) ≥ 155mmHg Subject has a history of maximum tolerable dose of ≥ 3 anti-hypertensive medications of different classes, one of which must be a diuretic (for at least two weeks prior to Medical Documentation Screening period) a. A documented history for a minimum of 3 months showing reasonable and aggressive efforts to manage hypertension prior to consent. This must the use of a broad variety of medications that have been used and failed or not tolerated Subject must have documented clinical evidence to support likelihood of angiographic findings > 80% whether it is DUS, CTa, MRa or other medical evidence New York Heart Association (NYHA) class I, II, or III the time of trial enrollment NOTE: When a subject has bilateral Renal Artery Stenosis both of which require stenting, it is recommended to treat both kidneys with an iCAST™ RX Stent System during the index procedure. In the event that a subject needs a renal stenting procedure staged for renal protection, it is important that the Investigator treats the second renal artery with an iCAST™ RX Stent System after 30 days of the index procedure. If subjects with bilateral stenosis have only one lesion that meets protocol that lesion should be treated per protocol. The recommendation is to NOT treat the second non-qualifying lesion, however if the operator feels strongly it is indicated, then they should treat per standard of care after 30-days post index procedure in order to comply with #10 Subjects with flash pulmonary edema are allowed into the trial should they meet all other and  Angiographic Anatomic Angiographic diameter renal artery stenosis ≥ 80% involving unilateral or bilateral renal arteries a. The degree of percent diameter stenosis for all lesions intended to be treated, must be confirmed via one of the following methods: i. Manual or automated measurement with calipers ii. Measured Flow Fraction Reserve (FFR) < 0.8 using a pressure wire iii. Measured translesional peak pressure gradient of > 21mmHg after induced hyperemia via dopamine or papaverine using a 4Fr or less catheter or pressure wire b. Subjects with 60-79% angiographic stenosis who have confirmed FFR < 0.8 may be enrolled Renal pole-to-pole length > 8cm (per visual estimate) Target lesion length ≤ 16mm per vessel (per visual estimate) Renal artery vessel diameter ≥ 5.0mm and ≤ 7.0mm (per visual estimate) Lesion originating ≤ 15mm of the renal ostium General Subject's estimated life expectancy is < 12 months


eligible ages (years): 20.0-999.0,  All  Acute Coronary Syndrome Subject must be at least 20 years of age Subject must have evidence of acute coronary syndrome (e.g., unstable angina, or STEMI) Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving 6-month or 12-month or longer duration of DAPT and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure  An elective surgical procedure is planned that would necessitate interruption of thienopyridines during the first 12 months post enrollment Patients with cardiogenic shock Subjects who have dialysis Women who are pregnant or breast feeing Less than 2years life expectancy by previous medical history Patients with hypersensitivity or contraindications for aspirin or clopidogrel Patients who need long-tem clopidogrel taking due to cerebral infarction or other diseases Patients who can not give written consent such as mental illness


eligible ages (years): 45.0-75.0,  All  Ischemic Heart Disease Obesity Stable Ischemic Heart Disease BMI 28 kg/m2  Known Diabetes Mellitus Repeated Fasting plasma glucose ≥ 7 mmol/L or Hba1c > 7 % Severe or moderate valve disease Main stem stenosis Severe heart failure, Ejection Fraction < 35 % Physical or mental disability which are expected to prevent completion of intervention Severe Chronic obstructive Pulmonary Disease (COPD) (FEV1 < 50 % of expected) or asthma Active cancer Severe kidney (GFR < 40 ml/hour) or severe liver disease Severe ischemia or arrhythmias during exercise test


eligible ages (years): 18.0-65.0,  All  Injury Due to Endoscopic Examination Transnasal Endoscopy Induced Epistaxis Transnasal Endoscopy Induced Nasal Pain All outpatients with epigastric discomfort (non-ulcer dyspepsia), aged 18-65 years are eligible for this study  Patients who have prior nasal trauma or surgery, recent or present upper gastrointestinal bleeding and coagulopathy are excluded from this study. Patients who are allergic to an anesthetic agent and who have uncontrolled hypertension or coronary artery disease are not recruited. Those who are uncooperative and unable to answer questions are also excluded


eligible ages (years): 18.0-999.0,  All  Acute Myocardial Infarction High risk ST elevation myocardial infarction evidenced by: ≥2 mm ST elevation in 2 anterior or lateral leads; or ≥2 mm ST elevation in 2 inferior coupled with ST depression in 2 contiguous anterior leads for a total ST deviation of ≥8 mm; or New left bundle branch block with at least 1 mm concordant ST elevation Multivessel CAD as evidenced by ≥1 significant (≥70% by visual assessment or FFR<0.80 for 50-70% stenosis) stenosis in non-IRA Successful IRA-PCI with <10% residual angiographic stenosis and TIMI III flow Written informed consent  Age ≤ 18 years Prior coronary artery bypass graft (CABG) surgery Administration of thrombolytic therapy Non-IRA stenosis is a chronic total occlusion or located in left main artery Hemodynamic instability evidenced by BP<90 mmHg, Killip class ≥2, need for inotropes/vasopressors Known renal insufficiency (estimated GFR < 50ml/min) Contraindication to CMR


eligible ages (years): 18.0-999.0,  All  Ventricular Tachycardia ≥ 18 years of age Structural heart disease (post-MI, dilated cardiomyopathy, sarcoid myopathy, hypertrophic cardiomyopathy, chagas-related cardiomyopathy, etc.) Planned for catheter-based ablation of VT All patients will have an existing ICD Accessibility of renal vasculature (determined by renal angiography) Ability to understand the requirements of the study Willingness to adhere to study restrictions and comply with all post procedural follow-up requirements  MI or CVA within 30 days Coronary Artery Bypass Graft (CABG) within 30 days of this procedure Known renovascular abnormalities that would preclude RSDN (eg, renal artery stenosis) GFR <30 ml/min (unless receiving dialysis) Life expectancy <1 year for any medical condition Any condition resulting in a contraindication to anticoagulation (e.g. GI bleeding) Inability to give informed consent Known pregnancy or positive -HCG within 7 days of procedure


eligible ages (years): 18.0-70.0,  All  Dilated Cardiomyopathy Diagnosis of dilated cardiomyopathy Left ventricular ejection fraction < 35% NYHA Functional classes of II-IV Symptomatic but not rapidly deteriorating 1 month before enrollment Signed informed consent  Contradictions and intolerance of the studied drugs supine systolic arterial blood pressure < 90 mmHg renal artery stenosis >50% pregnancy or lactation impaired renal function (estimated glomerular filtration rate < 60 ml/min/1.73m2 impaired liver function (total bilirubin >2 times upper limit of normal serum aspartate AST or alanine ALT >3 times the upper limit of normal) hemoglobin less than 8 mg/dl, hyperkalaemia (serum potassium >5.5mmol/l) obstructive lung disease advanced atrioventricular block


eligible ages (years): 18.0-999.0,  All  Coronary Artery Disease Coronary Artery Stenosis Coronary Disease Coronary Stenosis Subject must be at least 18 years of age at the time of signing the informed consent form Subject or a legally authorized representative must provide written Informed Consent prior to any study related procedure Subject must have evidence of myocardial ischemia (e.g., stable angina, unstable angina, post-infarct angina or silent ischemia) suitable for elective percutaneous coronary intervention (PCI). Subjects with stable angina or silent ischemia and < 70% diameter stenosis must have objective sign of ischemia as determined by one of the following, echocardiogram, nuclear scan, ambulatory ECG or stress ECG. In the absence of noninvasive ischemia, fractional flow reserve (FFR) must be done and indicative of ischemia Subject must be an acceptable candidate for coronary artery bypass graft (CABG) surgery Female subject of childbearing potential does not plan pregnancy for up to 1 year following the index procedure. For a female subject of childbearing potential, a pregnancy test must be performed with negative results known within 14 days (≤14 days) prior to the index procedure per site standard test Female subject is not breast-feeding at the time of the screening visit and will not be breast-feeding for up to 1 year following the index procedure Subject agrees to not participate in any other investigational clinical studies for a period of 1 year following the index procedure  Any surgery requiring general anesthesia or discontinuation of aspirin and/or P2Y12 inhibitor is planned within 12 months after the index procedure Subject has a known hypersensitivity or contraindication to device material (cobalt, chromium, nickel, tungsten, acrylic and fluoro polymers) and its degradants (everolimus, poly (L-lactide), poly (DL-lactide), lactide, lactic acid). Subject has a known contrast sensitivity that cannot be adequately pre-medicated Subject has a known allergic reaction, hypersensitivity or contraindication to Aspirin; or All P2Y12 inhibitors (including clopidogrel and ticlopidine, and prasugrel and ticagrelor when they become available); or Heparin and bivalirudin Subject had an acute myocardial infarction (AMI) within 7 days of the index procedure and both creatine kinase (CK) and creatine kinase myocardial-band isoenzyme (CK-MB) have not returned to within normal limits at the time of index procedure Subject is currently experiencing clinical symptoms consistent with new onset AMI, such as nitrate-unresponsive prolonged chest pain with ischemic ECG changes Subject has a cardiac arrhythmia as identified at the time of screening which at least one of the following is met Subject requires coumadin or any other agent for chronic oral anticoagulation


eligible ages (years): 18.0-999.0,  All  ST-elevation Myocardial Infarction. Multi Vessel Disease. Age ≥ 18 years Acute onset of chest pain of < 12 hours' duration ST-segment elevation ≥ 0.1 millivolt in ≥ 2 contiguous leads, signs of a true posterior infarction or documented newly developed left bundle branch block Culprit lesion in a major native vessel MVD (non-culprit vessels with angiographic stenosis >50%) Successful primary PCI  Pregnancy Known intolerance of acetylsalicylic acid, clopidogrel, heparin or contrast Inability to understand information or to provide informed consent Haemorrhagic diathesis or known coagulopathy Stent thrombosis Significant left main stem stenosis Cardiogenic shock at admittance


eligible ages (years): 70.0-999.0,  All  Vitamin D Deficiency Osteoporosis Osteopenia Age 70 or older woman African American ethnicity Non-institutionalized  De-compensated hepatic insufficiency Renal insufficiency with GFR estimated to be < 30 ml/min Gastrointestinal disorders that might affect absorption such as known malabsorption, celiac sprue, short gut or blind loop syndrome Institutionalized


eligible ages (years): 65.0-999.0,  All  Dementia Diagnosis of dementia or having a cognitive deficit measured as a score less than 25 on Mini-Mental State Examination  Fear of dogs, dog allergy or need of wheel chair


eligible ages (years): 18.0-90.0,  All  Type II Diabetes Mellitus age 18 or older type II diabetes poorly controlled diabetes (HbA1C >8 x 2 measurements, with goal < 8)  pregnancy non-English speaking or reading


eligible ages (years): 18.0-999.0,  All  ST Elevation (STEMI) Myocardial Infarction of Anterior Wall first time ST elevation anterior STEMI Significant chest discomfort and /or shortness of breath ST segment elevation (1.5 mV total) in two or more adjacent anterior precordial leads Successful reperfusion therapy (>TIMI grade 2 flow) either with thrombolytics or PTCA within 24 hours of onset of symptoms as documented by coronary angiography No previous history of an anterior AMI or previous ECG suggesting an old anterior AMI  Cardiogenic shock, acute heart failure or hypotension (Systolic BP < 90 mmHg) Previous MI Previous known decreased EF < 40% Atrial Fibrillation Persistent signs and symptoms of Post MI ischemia Requirement of pressors for maintenance of blood pressure Intra-aortic blood pump use Significant (moderate-severe) valvular stenosis, hypertrophic, restrictive or obstructive cardiomyopathy, constrictive pericarditis, primary pulmonary hypertension Severe congenital heart diseases Sustained ventricular tachycardia or ventricular fibrillation


eligible ages (years): 18.0-999.0,  All  Coronary Artery Disease Candidates for this study must meet ALL of the following Subject is at least 18 years old Subject requires single or multi-vessel percutaneous coronary intervention (PCI) of de novo or restenotic target lesion (including in-stent restenotic lesions). N.B. staged procedure will not be considered to meet the endpoint component of repeat revascularization if either of the following pre-catheterization procedure qualifying clinical laboratory values are met eGFR is less than 60 ml/min or creatinine is greater than 1.5 mg/dl Subject's lesion(s) is (are) amenable to stent treatment with currently available FDA-approved bare metal or drug eluting stents Subject is an acceptable candidate for non-emergency, urgent or emergency CABG Subject has clinical evidence of ischemic heart disease in terms of a positive functional study, or documented symptoms Documented stable angina pectoris [Canadian Cardiovascular Society Classification (CCS) 1, 2, 3, or 4], unstable angina pectoris with documented ischemia (Braunwald Class IB-C, IIB-C, or IIIB-C), non-ST segment elevation myocardial infarction, or documented silent ischemia  listed above and below with the exception that a target lesion of 70% or greater stenosis may be treated with or without symptoms or abnormal stress test) Subjects will be excluded from participation in the Cohort Study (and non-emergency PCI may not be performed in these patients at the non-SOS site) if ANY of the following conditions apply The patient is pregnant or breastfeeding Evidence of ST segment elevation myocardial infarction within 72 hours of the intended treatment on infarct related or non-infarct related artery Cardiogenic shock on presentation or during current hospitalization Left ventricular ejection fraction less than 20% Known allergies to: aspirin, clopidogrel (Plavix), prasugrel (Effient), and ticlopidine (Ticlid), heparin, bivalirudin, stainless steel, or contrast agent (which cannot be adequately premedicated) A platelet count less than 75,000 cells/mm3 or greater than 700,000 cells/mm3 or a WBC less than 3,000 cells/mm3 Acute or chronic renal dysfunction (creatinine less than 2.5 mg/dl or less than 150µmol/L) Subject is currently participating in an investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints. (Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials)


eligible ages (years): 60.0-85.0,  All  Computerized Assessment Feasibility and Validity Men and woman between the ages of 60-85, inclusive Cognitive function/impairment within appropriate ranges for the study (Mini-Mental State Exam scores of 10-30, inclusive)  Unable to complete computerized and standard pencil-and-paper based assessments


eligible ages (years): 60.0-999.0,  All  Malnutrition Man or woman aged more than 60 years old Living in a nursing home for at least 2 months Malnourished or at risk of malnutrition (MNA<23.5 or BMI<24 or albumin<35 g/l or weight loss of more than 5 kg in the last 6 months) Without dementia or with moderate dementia (MMSE > or =10/30) Able to walk without human assistance (technical assistance allowed) No vitamin D supplementation Able to follow the study procedures and agreed to consume oral supplement  Severe dementia (MMSE < 10/30) Enteral nutrition Severe renal or hepatic impairment Cancer with chemotherapy Uncontrolled diabetes Lactose intolerance Cow's milk protein allergy


eligible ages (years): 65.0-999.0,  All  Plaque, Amyloid Cognitive Deficits Participation in the AMI or 3C cohorts Group 1 Controls MMSE > 24 or > 26 for low and high levels of education, respectively Without memory impairment (for episodic memory) on the Free and Cued Selective Reminding Test RL/RI-16 items (FCSRT), free recall > 22 and total recall >42, according to the thresholds for population-based studies Without memory complaint Without dementia Group 2 Cognitively-impaired subjects without dementia and without memory complaints Mini Mental State Evaluation (MMSE) < 24 or < 26 for low and high levels of education, respectively With memory impairments according to the RL/RI-16 test (free recall≤22 and/or total recall ≤42), according to the thresholds for population-based studies defined by Auriacombe et al., 2010 Without memory complaint  Being left handed Presence of dementia (based on the clinical diagnosis) Presence of stroke Presence of Parkinson's disease Presence of a counter-indication for MRI Presence of a counter-indication for PET Scan with [18F]-Flutemetamol Presence of any health problem preventing travel to the imaging service of the University Hospital Being under the legal guardianship of another person or being unable to provide consent to participate Pregnant or breastfeeding woman


eligible ages (years): 60.0-999.0,  All  Alzheimer's Disease Elderly patients who are assisted in CRIA, diagnosed with Alzheimer's in use of rivastigmine or donepezil or galantamine, assisted by the "Program for special drugs" Be resident in the city of Araraquara / SP Accept part of pharmacotherapeutic follow-up Sign the Statement of Informed Consent Form (ICF)  Fold over pharmacotherapy follow-up Being institutionalized Patients unable to respond to collection instruments MMSE and CDR data Patient without phone contact


eligible ages (years): 18.0-999.0,  All  Cough Dyspnea Wheezing Presenting to the Emergency Department with cough, wheezing and/or dyspnea (shortness of breath) Referred for CXR and/or CT scan  Life threatening medical condition requiring immediate treatment Unable to sit up for a chest ultrasound Unable to consent Pregnant Unable to speak, read and write in English


eligible ages (years): 30.0-80.0,  All  Myocardial Infarction Patients who underwent primary PCI for acute STEMI and had >1 lesion in the culprit artery  Presence of LMCA lesion Cardiogenic shock Previous CABG operation Decision for CABG operation after primary PCI Severe valvular disease including aortic stenosis of mitral insufficiency Severe kidney disease (serum creatinine >2.5 mg/dl or patients on maintenance hemodialysis) Rejection of second PCI by the patient after the index event


eligible ages (years): 21.0-999.0,  All  Myocardial Infarction Inflammation Critical Illness ≥21 years of age admitted to the Medical Intensive or Coronary Care Units sepsis or respiratory failure clinically indicated troponin measurement within 24 hours of ICU admission  unstable angina or Type 1 MI percutaneous or surgical coronary revascularization within 7 days heart failure exacerbation primary valvular disorder aortic dissection infiltrative heart disease or hypertrophic cardiomyopathy myocarditis pulmonary embolism electrocardiogram with >1mm ST segment elevation in two consecutive leads serum cardiac troponin >99th percentile URL but no clear rise or fall pattern


eligible ages (years): 18.0-999.0,  All  Ventricular Rhythm From Artificial Pacing Indication for cardiac pacing  renal insufficiency iod allergy claustrophobia significant valvular disease recent acute coronary syndrome planned cardiac surgery ejection fraction of left ventricle less than 50% live expectancy less than 3 years expected non-compliance of the patient


eligible ages (years): 11.0-999.0,  All  Dental White Spots Dental Caries age 11 or older good health either gender present with at least two active white spot lesions on his/her anterior teeth at the start of the study have a moderate or high caries risk according to (Caries Management By Risk Assessment) rules require at least 12 additional months of full fixed appliance therapy from the time they are recruited for the study able to cooperate for treatment in the dental chair and follow at-home instructions have an understanding of the study willing to comply with all study procedures and protocols patient participant is able to provide written informed consent in English; if the participant is a minor, the parent/guardian is able to provide written informed consent in English and the patient participant is able to provide written assent in English  untreated cavitated lesions extensive composite fillings on buccal surfaces of front teeth/first bicuspids or more than one dental crown on front teeth/first bicuspids has sealants or fluoride releasing cements on the buccal surface of the anterior teeth in-office fluoride treatment in the last three months history of using any products containing CCP-ACP (casein phosphopeptides and amorphous calcium phosphate; MI paste, chewing gums or candies, etc.), prescription Fluoride products, and Chlorhexidine use in the last three months intrinsic or extremely heavy extrinsic staining any signs of fluorosis in the dentition any signs of morphologic/anatomical/developmental deviations in the teeth previous history of in office bleaching treatment subject not willing to stop the use of any other oral hygiene product than those prescribed/suggested


eligible ages (years): 50.0-80.0,  All  Osteoarthritis of the Hip unilateral, noninflammatory end-stage osteoarthritis of the hip willingness and ability to cooperate in the required post-operative therapy willingness and ability to provide written informed consent age 50-80 years  inflammatory arthropathies prior hip surgery prior infection of the hip severe morbidity severe osteoporosis inability to tolerate general anesthesia no contraindications to MRI e.g. pacemakers, claustrophobia neuromuscular disorder, vascular disorder or other conditions that could contribute to prosthesis instability, prosthesis fixation failure, or complications in postoperative care known alcohol or drug abuse unwillingness to participate


eligible ages (years): 18.0-80.0,  All  Rib Fracture Trauma must have above and be notated in our medical record  missing data


eligible ages (years): 35.0-65.0,  All  Myocardial Infarction Signed Informed Consent Form Patients having physical and mental ability to participate in the study Patients of both sexes aged 35 to 65 years Presence of documented ST-elevation myocardial infarction confirmed by ECG, as well as troponin I and CK-MB levels Presence of hemodynamically relevant stenosis of one artery (i.e., the infarct-related artery) confirmed by coronary angiography (CAG), with the occlusion of other arteries not exceeding 30%  A history of repeat or recurrent myocardial infarction A history of chronic heart failure (CHF) III-IV by New-York Heart Association (NYHA) Presence of left ventricular hypertrophy confirmed by echocardiography QRS complex exceeding 1.0 Ejection fraction less than 40% Presence of hemodynamically relevant stenosis exceeding 30% in several coronary arteries confirmed by CAG Type 1 diabetes mellitus Type 2 diabetes mellitus requiring pharmacotherapeutic correction with insulin Any severe concurrent disease A history of acute cerebrovascular accident (ACVA) within the 6 month period preceding the study


eligible ages (years): 40.0-75.0,  All  Hypertension Age between 40 Diameter of stenosis of renal artery or main branch of renal artery ≥60％. If diameter of stenosis is 60% , pressure difference between proximal and distal end ≥20 mm Hg (1mmHg=0.133kPa) or Captopril renography positive Systolic blood pressure before taking antihypertensive ≥180mmHg and/or diastolic blood pressure ≥110 mmHg; taking three antihypertensive including one diuretics with systolic blood pressure ≥140mmHg and/or ≥90 mmHg length of ipsilateral kidney is greater than 7.0cm  Estimated glomerular filtration rate (eGFR) ＜30 ml/ (min﹒1.73 m 2) [eGFR (mL/min/1.73 m2) = 186.3 * serum creatinine (mg/dl) -1.154 * Age-0.203 * 0.742 (female)[11] unstable condition and unable to tolerate interventional therapy anatomy of renal artery pathology not suitable for interventional therapy allergic to dihydropyridines III degree atrioventricular block contrast allergy  any known malignant tumor non-compliant, history of alcoholism or drug abuse


A 31-year-old woman with no previous medical problems comes to the emergency room with a history of 2 weeks of joint pain and fatigue. Initially she had right ankle swelling and difficulty standing up and walking, all of which resolved after a few days. For the past several days she has had pain, swelling and stiffness in her knees, hips and right elbow. She also reports intermittent fevers ranging from 38.2 to 39.4 degrees Celsius and chest pain.

eligible ages (years): 0.0-999.0,  All  Mental Disorder Diagnosed in Childhood Obsessive Compulsive Disorder Streptococcal Infection Tic Disorder Ages 4 years Fulfill for membership in the subgroup Presence of OCD and/or tic disorder Prepubertal symptom onset Abrupt onset and episodic (relapsing-remitting) symptom course Association between symptom exacerbations and GABHS infections Presence of choreiform movements or other neurological abnormalities during symptom exacerbations Because "time to relapse" is one of the primary outcome variables, children will not be eligible for randomization until their symptoms are in (at least partial) remission. At the time of randomization, symptom severity scores should be less than 50% of the child's previous maximum score on both the CY-BOCS and YGTSS, and no higher than a total score of 20 on the CY-BOCS or 30 on the YGTSS  Personal history of penicillin allergy History of rheumatic fever, including Sydenham's chorea Diagnosis of autism, schizophrenia or other psychotic disorder Chronic illnesses, particularly neurologic and immunologic disorders


eligible ages (years): 18.0-999.0,  All  Rheumatoid Arthritis Psoriatic Arthritis Polyarthritis Native English speaker Patient at the Rheumatology Clinic at Brigham and Women's Hospital, Boston, Massachusetts Diagnosis of rheumatoid arthritis, psoriatic arthritis, or seronegative polyarthritis


eligible ages (years): 18.0-999.0,  All  Inflammation Familial Mediterranean Fever Still's Disease, Adult-Onset Male or female subjects with inflammatory disease greater than or equal to 18 years of age Participation in NIH study number 94-AR-0105 ("Genetics and Pathophysiology of FMF and Related Disorders") Subjects presenting with active NOMID, MWS, FCAS, FMF, or adult Still's disease based on clinical signs/symptoms and/or biochemical markers such as acute phase reactants (CRP, SAA or ESR). Subjects need not have both clinical features and biochemical markers of disease to be enrolled. However, both clinical and laboratory responses will be evaluated in each subject for improvement as outcome measures (even improvement of laboratory values found to be within the normal range at baseline) NOMID, MWS, and FCAS: Diagnosis will be based on the history of classical features of disease including fevers, rash, joint involvement, CNS involvement. Approximately half of all subjects with these clinical syndromes are mutation negative; however, in the experience of the principal investigator these subjects show favorable clinical response to IL-1 blockade with anakinra. Therefore, subjects with or without recognized mutations in CIAS1 will be eligible to enroll in this study. Active disease will be defined as either the presence of aforementioned classical features, or a history of such features that became quiescent in the setting of therapy with anakinra. However, before a patient who has quiescent disease and is currently taking anakinra can receive study drug, he/she must fulfill for active disease after anakinra has been discontinued FMF will be diagnosed on the basis of documented presence of one or two mutant alleles of MEFV as well as the history of classical clinical features of FMF such as periodic fevers, rash, arthritis, arthralgia, or episodes of serositis. Subjects must be considered non-responsive to colchicine (up to 2 milligrams per day) on the basis of continued symptoms or flares (greater than or equal to one per month) or elevated acute phase reactants (ESR, CRP or SAA greater than or equal to 1.5 times the upper limit of normal between attacks) despite treatment with maximally tolerated doses of colchicine. Positive genetic test will be required for FMF to rule out the possibility that non-response to colchicine is due to misdiagnosis Adult Still's disease will be diagnosed on the basis of history of classical clinical features such as fevers, evanescent salmon-pink rash, arthritis, arthralgia, and myalgia. Active disease will be defined as presence of one or more of these features and/ or elevation of acute phase reactants (ESR, CRP or SAA greater than or equal to 1.5 times the upper limit of normal) Subjects currently treated with anakinra may be enrolled in this study even though autoinflammatory disease may be quiescent. For these subjects a history of active autoinflammatory disease prior to treatment with anakinra will be sufficient. Subjects must be greater than 48 hours from their last dose of anakinra before beginning IL-1 Trap therapy, and will not take anakinra for the remainder of their enrollment in the study. However, before study drug is administered subjects have to manifest signs of active disease as described above Stable dose of steroids, NSAIDs, DMARDs, or colchicine for four weeks prior to enrollment visit Females of childbearing potential (young women who have had at least one menstrual period regardless of age) must have a negative urine pregnancy test at screening and a negative serum pregnancy test at baseline prior to performance of any radiologic procedure or administration of study medication Women of childbearing age and men able to father a child, who are sexually active, who agree to use a form of effective birth control, including abstinence  Treatment with a live virus vaccine during 3 months prior to baseline visit. No live vaccines will be allowed throughout the course of this study Current treatment with TNF inhibitors or recent discontinuation of TNF inhibitors (use within less than 5 half-lives of TNF inhibitor agent) Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy. Subjects with current active TB, or recent close exposure to an individual with active TB are excluded from the study Chest x-ray read by a radiologist with pleural scarring and/or calcified granuloma consistent with prior TB Positive test for or prior history of HIV, Hepatitis B or C History or concomitant diagnosis of congestive heart failure History of malignancy. Subjects deemed cured of superficial malignancies such as cutaneous basal or squamous cell carcinomas, or in situ cervical cancer may be enrolled Known hypersensitivity to CHO cell derived biologicals or any components of IL 1 Trap Presence of any additional rheumatic disease or significant systemic disease. For example, major chronic infectious/ inflammatory/ immunologic disease (such as inflammatory bowel disease, psoriatic arthritis, spondyloarthropathy, SLE in addition to autoinflammatory disease) Presence of any of the following laboratory abnormalities at enrollment visit: creatinine greater than 1.5 times the upper limit of normal, WBC less than 3.6 x 10(9)/mm(3); platelet count less than 150,000 mm(3); ALT or AST greater than 2.0 x ULN (ALT/AST greater than 2.0 x ULN in an adult Still's disease patient would prompt a hepatology consult prior to enrollment unless these abnormalities are considered by the Principal Investigator to be reflective of the underlying Still's disease)


eligible ages (years): 18.0-999.0,  All  Rheumatoid Arthritis adult patients at least 18 years of age with moderate to severe active RA for at least 6 months inadequate response to a stable dose of MTX patients of reproductive potential must be using reliable methods of contraception  major surgery (including joint surgery) within 8 weeks before entering study, or planned surgery within 6 months after entering study prior treatment failure with an anti-tumor necrosis factor agent women who are pregnant or breast-feeding


eligible ages (years): 3.0-15.0,  All  Streptococcus Group A All children 3 to 15-years old with pharyngitis who are seen at a participating site will be invited to participate  Subjects whose parents are unable or unwilling to provide informed consent will be excluded from the study Children who are 13 years or older and unable or unwilling to provide informed consent will be excluded form the study


eligible ages (years): 18.0-999.0,  All  Scaphoid Fracture Mature skeleton Isolated, acute complete fracture of the mid third of the scaphoid  acute fractures of both hands one hand missing other injuries than scaphoid fractures rheumatoid, osteoarthritis or polyarthritis previous soft tissue injuries of the hand drug or alcohol abuse participant in trial during the previous month


eligible ages (years): 0.0-999.0,  All  Streptococcus Group A Informed consent will be obtained from all study participants. Children between 0 -17 years of age will be enrolled in the APSGN study. Children between 3-17 years of age and adults between 18-40 years will be enrolled in the ARF study. Children and adults of all ages will be enrolled in the RHD and invasive GAS studies


eligible ages (years): 18.0-999.0,  All  Arthritis, Psoriatic, Psoriasis Eighteen years of age or older Inflammatory arthropathy associated with psoriasis meet the ACR for PsA Patients with diagnosis of active and progressive PsA who have failure with conventional treatments  Significant concurrent medical diseases including cancer or a history of cancer, uncontrolled congestive heart failure, myocardial infarctions within 12 months or other clinically significant cardiovascular diseases, immunodeficiency syndromes or concomitant infectious diseases